Jiangxi Bio's Hong Kong IPO Prospectus Expires

Stock News

Oct 13

Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th. CICC and CMB International Securities served as joint sponsors for the listing application.

According to the prospectus, citing Frost & Sullivan data, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in both China and globally. Based on 2024 sales volumes, the company holds market shares of 65.8% in China and 36.6% worldwide.

Tetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing toxins produced by Clostridium tetani, the bacteria responsible for tetanus infections, thereby preventing and treating tetanus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113572854"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113572854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113572854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113572854","market":"nz","top_or_hot":-1,"title":"Jiangxi Bio's Hong Kong IPO Prospectus Expires","media":"Stock News","content":"<p>Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th. CICC and CMB International Securities served as joint sponsors for the listing application.</p>\n<p>According to the prospectus, citing Frost & Sullivan data, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in both China and globally. Based on 2024 sales volumes, the company holds market shares of 65.8% in China and 36.6% worldwide.</p>\n<p>Tetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing toxins produced by Clostridium tetani, the bacteria responsible for tetanus infections, thereby preventing and treating tetanus.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Bio's Hong Kong IPO Prospectus Expires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Bio's Hong Kong IPO Prospectus Expires\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-13 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th. CICC and CMB International Securities served as joint sponsors for the listing application.</p>\n<p>According to the prospectus, citing Frost & Sullivan data, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in both China and globally. Based on 2024 sales volumes, the company holds market shares of 65.8% in China and 36.6% worldwide.</p>\n<p>Tetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing toxins produced by Clostridium tetani, the bacteria responsible for tetanus infections, thereby preventing and treating tetanus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4614","symbol_name":"Manus概念股","start_time":0,"source_url":"","article_id":"1113572854","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113572854","pubTimestamp":1760317334,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4614":"Manus概念股","HSCEI":"国企指数","07226":"南方两倍做多恒科","HSTECH":"恒生科技指数","YANG":"三倍做空富时中国ETF-Direxion"},"translate_title":"江西生物港股IPO招股书失效","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07226":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th. CICC and CMB International Securities served as joint sponsors for the listing application.\nAccording to the prospectus, citing Frost & Sullivan data, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in both China and globally. Based on 2024 sales volumes, the company holds market shares of 65.8% in China and 36.6% worldwide.\nTetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing toxins produced by Clostridium tetani, the bacteria responsible for tetanus infections, thereby preventing and treating tetanus.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}